Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 72% of modeled bridge. Strengths: Occupancy Rate, Net-to-Gross Ratio. Risks: Bed Count. Risk-adjusted uplift: $14.7M (vs $20.3M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $7.7M | $7.7M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $7.4M | $213K | $7.7M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $1.2M | $3.5M | $4.7M | $14.8M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $247K | $247K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 20.9% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $1.9M | $3.9M | $5.8M | $7.7M | $7.7M | $7.7M | $7.7M |
| Denial Rate Reduction | $0 | $1.9M | $3.8M | $5.7M | $7.7M | $7.7M | $7.7M | $7.7M |
| A/R Days Reduction | $0 | $1.6M | $3.1M | $4.7M | $4.7M | $4.7M | $4.7M | $4.7M |
| Clean Claim Rate | $0 | $124K | $247K | $247K | $247K | $247K | $247K | $247K |
| Cumulative | $0 | $5.5M | $11.1M | $16.5M | $20.3M | $20.3M | $20.3M | $20.3M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $20.3M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 47% / 6.8x | 51% / 8.0x | 55% / 9.1x | 57% / 9.6x | 59% / 10.2x |
| 9.0x | 42% / 5.7x | 46% / 6.7x | 50% / 7.7x | 52% / 8.2x | 54% / 8.7x |
| 10.0x | 37% / 4.8x | 42% / 5.7x | 46% / 6.6x | 48% / 7.0x | 50% / 7.5x |
| 11.0x | 32% / 4.1x | 37% / 4.9x | 42% / 5.7x | 44% / 6.1x | 46% / 6.5x |
| 12.0x | 28% / 3.5x | 33% / 4.2x | 38% / 5.0x | 40% / 5.3x | 42% / 5.7x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline -7% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 6.9x, adding 1.5 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $93.1M | — | $93.1M | 24.1% |
| Year 1 | $95.9M | +$13.6M | $109.4M | 28.3% |
| Year 2 | $98.8M | +$20.3M | $119.1M | 30.8% |
| Year 3 | $101.7M | +$20.3M | $122.0M | 31.6% |
| Year 4 | $104.8M | +$20.3M | $125.1M | 32.4% |
| Year 5 | $107.9M | +$20.3M | $128.2M | 33.2% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $3.9M | $5.8M | $7.7M | $9.3M |
| Denial Rate Reductio | $3.8M | $5.7M | $7.7M | $9.2M |
| A/R Days Reduction | $2.4M | $3.5M | $4.7M | $5.6M |
| Clean Claim Rate | $124K | $185K | $247K | $297K |
| Total | $10.2M | $15.2M | $20.3M | $24.4M |
Peer Context — Where This Hospital Sits
Key metrics vs 113 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 24.1% | -5.2% | 2.8% | 16.9% | P83 |
| Net-to-Gross | 9.9% | 10.0% | 14.5% | 20.9% | P23 |
| Occupancy | 76.3% | 52.9% | 64.4% | 75.3% | P78 |
| Rev/Bed | $1.6M | $825K | $1.2M | $1.4M | P82 |
| Exp/Bed | $1.2M | $739K | $970K | $1.3M | P69 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.